Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Solithromycin - Melinta Therapeutics

Drug Profile

Solithromycin - Melinta Therapeutics

Alternative Names: CEM-101; OP-1068; T-4288

Latest Information Update: 28 Aug 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Optimer Pharmaceuticals
  • Developer Cempra Pharmaceuticals; FUJIFILM Toyama Chemical; Melinta Therapeutics; Toyama Chemical
  • Class Anti-infectives; Anti-inflammatories; Antibacterials; Antibronchitics; Antimalarials; Eye disorder therapies; Hepatoprotectants; Heterocyclic bicyclo compounds; Ketolides; Macrolides; Oxazoles; Pyrans; Small molecules
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Community-acquired pneumonia; Otorhinolaryngological infections
  • Phase III Bronchitis; Chlamydial infections; Gonorrhoea; Respiratory tract infections; Sinusitis; Urethritis
  • Phase II Chronic obstructive pulmonary disease; Non-alcoholic steatohepatitis
  • No development reported Anthrax; Bacterial infections; Enterococcal infections; Eye disorders; Legionella infections; Malaria; Methicillin-resistant Staphylococcus aureus infections; Mycobacterium avium complex infections; Mycoplasma infections; Obstetric and gynaecological infections; Otitis media; Tularaemia

Most Recent Events

  • 28 Aug 2022 No recent reports of development identified for preclinical development in Eye-disorders in USA (Ophthalmic)
  • 25 Apr 2019 Preregistration for Otorhinolaryngological infections in Japan (PO)
  • 28 Oct 2018 No recent reports of development identified for phase-I development in Community-acquired-pneumonia(In volunteers) in Japan (PO, Tablet)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top